43 results
8-K
EX-99.1
ALGS
Aligos Therapeutics Inc
12 Mar 24
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results
4:06pm
) for the year ended December 31, 2022.
Research and development (R&D) expenses for the three months ended December 31, 2023 were $22.3 million, compared … Ended
Twelve Months Ended
December 31,
(Unaudited)
(audited) (1)
Revenue from Collaborations
Revenue from Customers
Operating Expenses:
Research
424B3
ALGS
Aligos Therapeutics Inc
28 Nov 23
Prospectus supplement
4:01pm
and ALG-125755 clinical trials;
the scope, progress, results and costs related to the research and development of our pipeline;
the timing
8-K
EX-99.1
ennqn4 wbewj8
2 Nov 23
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results
4:05pm
8-K
EX-99.1
nqfzu
3 Aug 23
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2023 Financial Results
4:05pm
8-K
EX-99.1
ee1ut4xeg4ohpx pp7vm
4 May 23
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2023 Financial Results
4:05pm
CORRESP
35pj4
22 Dec 22
Correspondence with SEC
12:00am
UPLOAD
dwgq7d2 gd
8 Dec 22
Letter from SEC
12:00am
8-K
EX-99.1
7e6zzi82eo6dqy7luxk
2 Nov 22
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2022 Financial Results
4:05pm
8-K
EX-99.1
50ep2zo1 bum74u1xe
4 Aug 22
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2022 Financial Results
4:06pm
8-K
EX-99.1
6xfm1fu
4 May 22
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2022 Financial Results
4:06pm
8-K
EX-99.1
oku 8nfeb75f
10 Mar 22
Aligos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights
4:05pm